A new study shows datopotamab deruxtecan (Dato-DXd; Datroway; AstraZeneca) offers a meaningful survival advantage in a subgroup of patients with metastatic triple-negative breast cancer (mTNBC) who are not eligible for immunotherapy, according to…
Dato-DXd Shows Promise as First-Line Therapy in Metastatic TNBC | Pharmacy Times
